319 related articles for article (PubMed ID: 33753457)
1. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
[TBL] [Abstract][Full Text] [Related]
5. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
6. Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation.
Haroun-Izquierdo A; Lanuza PM; Pfefferle A; Netskar H; Ask EH; Törlén J; Björklund A; Sohlberg E; Malmberg KJ
Transplant Cell Ther; 2023 Jun; 29(6):376.e1-376.e11. PubMed ID: 36966873
[TBL] [Abstract][Full Text] [Related]
7. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.
Betts BC; Veerapathran A; Pidala J; Yang H; Horna P; Walton K; Cubitt CL; Gunawan S; Lawrence HR; Lawrence NJ; Sebti SM; Anasetti C
Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077684
[TBL] [Abstract][Full Text] [Related]
8. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA
Bone Marrow Transplant; 2017 Mar; 52(3):438-444. PubMed ID: 27819684
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Choi SW; Braun T; Chang L; Ferrara JL; Pawarode A; Magenau JM; Hou G; Beumer JH; Levine JE; Goldstein S; Couriel DR; Stockerl-Goldstein K; Krijanovski OI; Kitko C; Yanik GA; Lehmann MH; Tawara I; Sun Y; Paczesny S; Mapara MY; Dinarello CA; DiPersio JF; Reddy P
Lancet Oncol; 2014 Jan; 15(1):87-95. PubMed ID: 24295572
[TBL] [Abstract][Full Text] [Related]
13. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
15. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.
Bader CS; Pavlova A; Lowsky R; Muffly LS; Shiraz P; Arai S; Johnston LJ; Rezvani AR; Weng WK; Miklos DB; Frank MJ; Tamaresis JS; Agrawal V; Bharadwaj S; Sidana S; Shizuru JA; Fernhoff NB; Putnam A; Killian S; Xie BJ; Negrin RS; Meyer EH
Blood Adv; 2024 Mar; 8(5):1105-1115. PubMed ID: 38091578
[TBL] [Abstract][Full Text] [Related]
16. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
17. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.
Rosenthal J; Pawlowska A; Bolotin E; Cervantes C; Maroongroge S; Thomas SH; Forman SJ
Pediatr Blood Cancer; 2011 Jul; 57(1):142-6. PubMed ID: 21557459
[TBL] [Abstract][Full Text] [Related]
18. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.
Khimani F; Kim J; Chen L; Dean E; Rizk V; Betts B; Nishihori T; Locke F; Mishra A; Perez L; Ayala E; Kharfan-Dabaja M; Nieder M; Fernandez H; Anasetti C; Pidala J
Bone Marrow Transplant; 2017 Jul; 52(7):1003-1009. PubMed ID: 28368376
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
